CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Merck & Co Inc - USD - MRK CFD

106.01
0.68%
0.20
Low: 105.68
High: 106.32
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.20
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Merck & Co Inc ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 105.29
Open* 105.75
1-Year Change* 30.98%
Day's Range* 105.68 - 106.32
52 wk Range 72.88-115.49
Average Volume (10 days) 8.08M
Average Volume (3 months) 186.31M
Market Cap 267.18B
P/E Ratio 17.46
Shares Outstanding 2.54B
Revenue 58.97B
EPS 6.04
Dividend (Yield %) 2.77092
Beta 0.37
Next Earnings Date Feb 2, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 30, 2023 106.01 0.69 0.66% 105.32 106.40 105.01
Jan 27, 2023 105.29 -0.40 -0.38% 105.69 106.48 105.01
Jan 26, 2023 106.73 -1.43 -1.32% 108.16 108.30 105.71
Jan 25, 2023 108.49 1.14 1.06% 107.35 109.83 107.35
Jan 24, 2023 108.43 -0.64 -0.59% 109.07 109.58 107.00
Jan 23, 2023 109.70 -0.03 -0.03% 109.73 110.26 109.06
Jan 20, 2023 109.82 0.98 0.90% 108.84 109.89 108.48
Jan 19, 2023 109.77 2.03 1.88% 107.74 110.08 107.74
Jan 18, 2023 108.72 -1.11 -1.01% 109.83 110.01 108.48
Jan 17, 2023 110.35 -1.51 -1.35% 111.86 112.38 110.22
Jan 13, 2023 112.09 1.72 1.56% 110.37 112.34 110.00
Jan 12, 2023 111.65 1.40 1.27% 110.25 112.00 109.91
Jan 11, 2023 110.95 2.73 2.52% 108.22 111.21 108.22
Jan 10, 2023 110.67 1.13 1.03% 109.54 111.92 109.54
Jan 9, 2023 110.25 -4.52 -3.94% 114.77 114.77 109.83
Jan 6, 2023 114.72 0.93 0.82% 113.79 115.39 113.76
Jan 5, 2023 113.48 2.26 2.03% 111.22 113.81 111.22
Jan 4, 2023 111.99 0.38 0.34% 111.61 112.51 111.12
Jan 3, 2023 111.06 0.65 0.59% 110.41 111.10 109.36
Dec 30, 2022 110.85 -0.14 -0.13% 110.99 111.30 110.01

Merck & Co Inc - USD Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 39807 40122 42294 39121 41518 48704
Revenue 39807 40122 42294 39121 41518 48704
Cost of Revenue, Total 13502 12640 13065 11060 11583 13241
Gross Profit 26305 27482 29229 28061 29935 35463
Total Operating Expense 34959 34101 33995 31821 36545 36166
Selling/General/Admin. Expenses, Total 9844 10028 10067 9421 8908 9615
Research & Development 6519 7495 7854 8555 10102 10281
Unusual Expense (Income) 5094 3938 3009 2785 5952 3029
Operating Income 4848 6021 8299 7300 4973 12538
Interest Income (Expense), Net Non-Operating -496 -116 10 -636 421 873
Other, Net 307 616 392 507 469 468
Net Income Before Taxes 4659 6521 8701 7171 5863 13879
Net Income After Taxes 3941 5043 6482 5606 4523 12358
Minority Interest -21 -24 27 84 -4 -13
Net Income Before Extra. Items 3920 5019 6509 5690 4519 12345
Net Income 3920 2394 6220 9843 7067 13049
Income Available to Common Excl. Extra. Items 3920 5019 6509 5690 4519 12345
Income Available to Common Incl. Extra. Items 3920 2394 6220 9843 7067 13049
Diluted Net Income 3920 2394 6220 9843 7067 13049
Diluted Weighted Average Shares 2787 2748 2679 2580 2541 2538
Diluted EPS Excluding Extraordinary Items 1.40653 1.82642 2.42964 2.20543 1.77843 4.86407
Dividends per Share - Common Stock Primary Issue 1.84 2.36 1.99 2.26 2.48 2.64
Diluted Normalized EPS 6.11554 4.03264 4.13343 3.96379 4.69927 6.81007
Total Extraordinary Items -2625 -289 4153 2548 704
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 10627 11402 13154 13521 15901
Revenue 10627 11402 13154 13521 15901
Cost of Revenue, Total 2984 3029 3402 3827 5334
Gross Profit 7643 8373 9752 9694 10567
Total Operating Expense 8095 9788 8338 9946 10332
Selling/General/Admin. Expenses, Total 2185 2279 2331 2820 2302
Research & Development 2404 2611 2437 3061 2569
Unusual Expense (Income) 522 1869 168 238 127
Operating Income 2532 1614 4816 3575 5569
Interest Income (Expense), Net Non-Operating 345 -27 448 110 -983
Other, Net 110 130 2 224 275
Net Income Before Taxes 2987 1717 5266 3909 4861
Net Income After Taxes 2749 1214 4571 3824 4307
Minority Interest -4 -1 -4 -4 3
Net Income Before Extra. Items 2745 1213 4567 3820 4310
Total Extraordinary Items 434 332 0 -62 0
Net Income 3179 1545 4567 3758 4310
Income Available to Common Excl. Extra. Items 2745 1213 4567 3820 4310
Income Available to Common Incl. Extra. Items 3179 1545 4567 3758 4310
Diluted Net Income 3179 1545 4567 3758 4310
Diluted Weighted Average Shares 2540 2540 2536 2535 2537
Diluted EPS Excluding Extraordinary Items 1.08071 0.47756 1.80087 1.5069 1.69886
Dividends per Share - Common Stock Primary Issue 0.65 0.65 0.65 0.69 0.69
Diluted Normalized EPS 1.44992 1.13784 2.01068 1.9997 1.52074
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 30614 24766 25875 27483 27764 30266
Cash and Short Term Investments 14341 8498 8864 10450 8062 8096
Cash & Equivalents 6515 6092 7965 9676 8062 8096
Short Term Investments 7826 2406 899 774 0
Total Receivables, Net 7018 6873 7071 6778 7851 9230
Accounts Receivable - Trade, Net 7018 6873 7071 6778 7851 9230
Total Inventory 4866 5096 5440 5978 6310 5953
Other Current Assets, Total 4389 4299 4500 4277 5541 6987
Total Assets 95377 87872 82637 84397 91588 105694
Property/Plant/Equipment, Total - Net 12026 12439 13291 16126 17986 19279
Property/Plant/Equipment, Total - Gross 27775 29041 29615 33812 36968 37471
Accumulated Depreciation, Total -15749 -16602 -16324 -17686 -18982 -18192
Goodwill, Net 18162 18284 18253 19425 20238 21264
Intangibles, Net 17305 14183 11431 14196 14604 22933
Long Term Investments 12131 12892 6233 1889 1371 966
Other Long Term Assets, Total 5139 5308 7554 5278 9625 10986
Total Current Liabilities 17204 18614 22206 22220 27327 23872
Accounts Payable 2807 3102 3318 3738 4594 4609
Accrued Expenses 10170 10263 10073 12453 13053 13859
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 568 3057 5308 3610 6431 2412
Other Current Liabilities, Total 3659 2192 3507 2419 3249 2992
Total Liabilities 55289 53536 55936 58490 66271 67510
Total Long Term Debt 24274 21353 19806 22736 25360 30690
Long Term Debt 24274 21353 19806 22736 25360 30690
Deferred Income Tax 5077 2219 1702 1470 1015 3441
Minority Interest 220 233 181 94 87 73
Other Liabilities, Total 8514 11117 12041 11970 12482 9434
Total Equity 40088 34336 26701 25907 25317 38184
Common Stock 1788 1788 1788 1788 1788 1788
Additional Paid-In Capital 39939 39902 38808 39660 39588 44238
Retained Earnings (Accumulated Deficit) 44133 41350 42579 46602 47362 53696
Treasury Stock - Common -40546 -43794 -50929 -55950 -56787 -57109
Unrealized Gain (Loss) -3 -61 -78 18 0 0
Other Equity, Total -5223 -4849 -5467 -6211 -6634 -4429
Total Liabilities & Shareholders’ Equity 95377 87872 82637 84397 91588 105694
Total Common Shares Outstanding 2748.73 2696.61 2592.56 2539.02 2530.23 2527.6
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 26909 28665 31058 30266 31184
Cash and Short Term Investments 6981 8575 10016 8096 8928
Cash & Equivalents 6981 8575 10016 8096 8556
Total Receivables, Net 8235 7843 8571 9230 9828
Accounts Receivable - Trade, Net 8235 7843 8571 9230 9828
Total Inventory 6402 5499 5603 5953 5774
Other Current Assets, Total 5291 6748 6868 6987 6654
Total Assets 90847 90688 93494 105694 106668
Property/Plant/Equipment, Total - Net 18295 18064 18565 19279 19747
Property/Plant/Equipment, Total - Gross 37027 36300 36720 37471 38245
Accumulated Depreciation, Total -18732 -18236 -18155 -18192 -18498
Goodwill, Net 20212 18873 18862 21264 21258
Intangibles, Net 14401 13622 13384 22933 23022
Long Term Investments 1195 1105 1013 966 959
Other Long Term Assets, Total 9835 10359 10612 10986 10498
Total Current Liabilities 26361 21906 23728 23872 22316
Accounts Payable 4034 3897 3366 4609 3715
Accrued Expenses 11911 12888 14214 13859 14051
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 7251 2488 3534 2412 1208
Other Current Liabilities, Total 3165 2633 2614 2992 3342
Total Liabilities 63902 57394 57700 67510 65785
Total Long Term Debt 24002 24033 22907 30690 30586
Long Term Debt 24002 24033 22907 30690 30586
Deferred Income Tax 1204 1489 1527 3441 3071
Minority Interest 94 94 69 73 70
Other Liabilities, Total 12241 9872 9469 9434 9742
Total Equity 26945 33294 35794 38184 40883
Common Stock 1788 1788 1788 1788 1788
Additional Paid-In Capital 39613 44039 44149 44238 44275
Retained Earnings (Accumulated Deficit) 48888 48777 51691 53696 56252
Treasury Stock - Common -56722 -56682 -57244 -57109 -57063
Unrealized Gain (Loss) 0 0 0 0
Other Equity, Total -6622 -4628 -4590 -4429 -4369
Total Liabilities & Shareholders’ Equity 90847 90688 93494 105694 106668
Total Common Shares Outstanding 2531.3 2532.75 2525.32 2527.6 2528.38
Short Term Investments 372
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 3941 2418 6193 9777 4523 12358
Cash From Operating Activities 10376 6447 10922 13440 10253 14109
Cash From Operating Activities 5441 4637 4519 3652 1669 1578
Deferred Taxes -1521 -2621 -509 -556 -566 187
Non-Cash Items 5116 7034 2272 2634 7411 2189
Cash Taxes Paid 1800 4900 1500 4500 2700 2400
Cash Interest Paid 686 723 777 841 822 779
Changes in Working Capital -2601 -5021 -1553 -2067 -4601 -3839
Cash From Investing Activities -3210 2679 4314 -2629 -9443 -16555
Capital Expenditures -1614 -1888 -2615 -3473 -4429 -4448
Other Investing Cash Flow Items, Total -1596 4567 6929 844 -5014 -12107
Cash From Financing Activities -9044 -10006 -13160 -8861 -2832 2593
Financing Cash Flow Items -118 -195 -325 5 -436 8210
Total Cash Dividends Paid -5124 -5167 -5172 -5695 -6215 -6610
Issuance (Retirement) of Stock, Net -2495 -3515 -8500 -4419 -1192 -638
Issuance (Retirement) of Debt, Net -1307 -1129 837 1248 5011 1631
Foreign Exchange Effects -131 457 -205 17 253 -133
Net Change in Cash -2009 -423 1871 1967 -1769 14
Amortization 1817 1636
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 3186 3963 8534 12358 4307
Cash From Operating Activities 1791 4281 9078 14109 4761
Cash From Operating Activities 396 749 1148 1578 421
Amortization 534 871 1231 1636 699
Deferred Taxes -10 29 28 187 -338
Non-Cash Items -211 2324 1931 2189 971
Cash Interest Paid 217 363 570 779 211
Changes in Working Capital -2104 -3655 -3794 -3839 -1299
Cash From Investing Activities -738 -3445 -4506 -16555 -1173
Capital Expenditures -1134 -2068 -3240 -4448 -984
Other Investing Cash Flow Items, Total 396 -1377 -1266 -12107 -189
Cash From Financing Activities -2098 -340 -2614 2593 -3086
Financing Cash Flow Items -97 8302 8243 8210 -103
Total Cash Dividends Paid -1645 -3318 -4967 -6610 -1745
Issuance (Retirement) of Stock, Net 9 -188 -754 -638 12
Issuance (Retirement) of Debt, Net -365 -5136 -5136 1631 -1250
Foreign Exchange Effects -97 -19 -65 -133 -55
Net Change in Cash -1142 477 1893 14 447
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.7946 222977541 3070577 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.4365 137837792 697229 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.6269 117311329 -480300 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8972 48100919 2106251 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.5839 40157172 -566255 2022-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 1.2207 30950448 1429537 2022-09-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 1.0307 26133153 -662798 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9382 23786901 -2349731 2021-12-31 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.8865 22475032 1102748 2022-09-30 LOW
BofA Global Research (US) Research Firm 0.8749 22181659 303733 2022-09-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.8648 21925926 114408 2022-09-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7772 19704612 -575045 2022-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7269 18429683 -1379488 2022-09-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 0.7146 18119118 1683829 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7136 18091768 -228546 2022-09-30 LOW
Managed Account Advisors LLC Investment Advisor 0.7031 17825870 2268172 2022-09-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.6747 17107406 366748 2022-09-30 LOW
Mellon Investments Corporation Investment Advisor/Hedge Fund 0.6745 17102276 -39695 2022-09-30 LOW
State Farm Insurance Companies Insurance Company 0.5613 14231200 0 2022-09-30 LOW
Invesco Advisers, Inc. Investment Advisor 0.5587 14166387 -614838 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Merck - USD Company profile

Merck & Co., Inc. (MRK) is a healthcare company dealing in pharmaceuticals and animal health. Founded in 1891, Merck is headquartered in Kenilworth, New Jersey. 

The company provides pharmaceutical products around the world, offering an array of human healthcare solutions designed for areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular and diabetes. 

Apart from prescription medicines, Merck is known for its vaccine products for preventive diseases. A predecessor company to the present-day Merck made the first smallpox vaccine for commercial use in the United States in 1898 and was the maker of HPV vaccine Gardasil and painkiller Vioxx.

This biopharmaceutical company engages in research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. In 2021, Merck invested $12.2bn in research and development, especially to counter and help win the fight against coronavirus. It’s molnupiravir was given emergency use authorisation by the United States Food and Drug Administration (FDA) to counter mild-to-moderate Covid-19 in adults. 

Merck puts equal emphasis on animal health through Merck Animal Health, a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services.

The company engages and partners with several experts for early-stage science, clinical-stage programs, to deliver therapies and more. GlaxoSmithKline PLC (GSK), Johnson & Johnson (JJ) and many others are actively engaged with Merck.

Being more than a century old, Merck made it through two world wars and was a big part of the economic and business history of American public markets. Post-First World War, authorities seized the subsidiary of a German chemical maker to prevent the Kaiser from profiteering from American needs. Merck was re-established as an American corporation after the Second World War ended. 

The company went public on the New York Stock Exchange in 1946 under the symbol ‘MRK’.

Industry: Pharmaceuticals (NEC)

2000 Galloping Hill Road
KENILWORTH
NEW JERSEY 07033
US

Income Statement

  • Annual
  • Quarterly

News

Global Currencies.

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis

USD, GBP/USD, EUR/USD forecasts for the week ahead.

16:33, 27 January 2023
Businessman representing recessionary, stagflation or inflation economies with graphs of the stock market as a concept of raw material. Financial world crisis concept.

WTI, Gold, Silver – commodities weekly forecast for the week ahead

Strength to strength in the commodity space, however, topside exhaustion begins to creep in

13:53, 27 January 2023
Rising stock market chart on a trading board background.

S&P 500, Nasdaq, DAX 40, Hang Seng technical update

Can the S&P 500 hold above its 2022 descending trend line?

12:44, 26 January 2023
photo illustration an Amazon logo seen displayed on a smartphone.

Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending

AMZN Q4 earnings preview and technical analysis

09:59, 25 January 2023
Bank of Canada outlook

Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike

Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.

15:49, 24 January 2023

People also watch

US100

11,873.20 Price
-0.430% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0072%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

22,956.25 Price
+0.730% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

77.43 Price
-0.820% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

2.69 Price
-1.150% 1D Chg, %
Long position overnight fee -0.0489%
Short position overnight fee 0.0279%
Overnight fee time 22:00 (UTC)
Spread 0.005

Market analysis

Benjamin Franklin’s face on a $100 bill

USD forecast: DXY slides in risk-off market sentiment

17:16, 30 January 2023
A large Amazon logo displayed on the side of an Amazon building

Amazon stock forecast: Where next for AMZN amid massive layoffs?

17:55, 23 January 2023
Australian dollar bills

Australian dollar forecast: Will AUD outperform in 2023?

17:49, 20 January 2023

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading